Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Targeting BMI-1 with PLGA–PEG nanoparticle-containing PTC209 modulates the behavior of human glioblastoma stem cells and cancer cells

Fig. 2

Characteristics of PTC209-loaded PLGA–PEG nanoparticle conjugated with anti-CD133 monoclonal antibodies (Nano-PTC209). a Transmission electron microscopy (TEM) of Nano-PTC209. TEM images have shown that the mean size of Nano-PTC209 was ~ 75 nm. b Dynamic light-scattering analysis of Nano-PTC209 has indicated the mean size of 158.3 ± 5.8 nm, the mean intensity of 73.6 ± 4.9%, and the mean polydispersity index of 0.22 ± 0.02. c FTIR spectrum of Nano-PTC209 indicated four peaks at 1655.50, 3434.21, 1014.28–1107.64, and 666.47 cm−1, which were corresponding to the conjugated carbonyl group, the –NH2 stretching band, C–O–C interactions, and bromide, respectively. d The PTC209 release pattern of nanoparticles in PBS with and without 10% FBS. The comparison of the two groups was evaluated at different time points. Data are expressed as the mean ± SD. * indicates P < 0.05

Back to article page